Therapeutic Areas

Oncology & Hematology Full-Service CRO and Consultancy

Advance your Novel Oncology Therapies to Approval and Commercial Success

When the complexities of designing and executing cancer trials in a highly competitive market can mean delays in delivering urgently needed treatments to patients, it pays to have a trusted partner by your side. In the past five years, our experienced teams have helped clients with more than 435 oncology and hematology studies, prepared more than 60 INDs/CTAs, and more than 35 US and European regulatory marketing applications.

Our expertise encompasses traditional cancer treatments, devices/diagnostics, and specialized therapies, including vaccines, gene and cell therapies, and immunotherapies.

Developing an oncology or hematology therapy?  Let’s Talk.

Oncology/Hematology Experience in the Past 5 Years


Clinical Trials & Consulting Projects


Marketing Applications (NDAs, BLAs, MAAs) Prepared


of global operations team members have oncology/hematology experience

Clinical Trial & Regulatory Consulting Expertise for Cancers & Blood Disorders

Our expertise allows us to confidently handle the most complex trials and patient populations with the attention and focus needed to navigate the cancer and hematology landscape.  

Whatever your challenges are, Veristat provides creative and strategic approaches to inform your decision-making, mitigate trial risks, prove safety and efficacy, and achieve approval success. Our regulatory and clinical development experts are poised to launch your oncology or hematology trial:

Scientific Excellence Across Cancer & Hematology Indications

Solid Tumors

  • Brain
  • Breast
  • Gastrointestinal
  • Lung
  • Skin
  • and more...
solid tumor indications

Rare Cancers

  • Acute Myeloid Leukemia
  • Glioblastoma
  • Hodgkin’s Lymphoma
  • Multiple Myeloma
  • Pancreatic
  • and more...
Rare cancer indications

Blood Diseases

  • Beta-Thalassemia
    Sickle Cell Anemia
  • Wiskott-Aldrich Syndrome 
    and more...
Hematology indications

Case Study: Successful Full-Service, Randomized Pancreatic Cancer Phase II Trial

A clinical-stage biopharmaceutical company approached Veristat in a multi-center, randomized Phase II study of a modified synthetic peptide in patients with exocrine pancreatic cancer. The study aimed to establish the efficacy and safety of combinations of the therapy in patients with stage IV exocrine pancreatic cancer. Learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges, including slow recruitment, data cleansing post-MSU, and site staffing.


Randomized Pancreatic Cancer Phase II_Full
"By partnering with a like-minded, scientifically focused company such as Veristat, we have found a core team of high caliber collaborators who can help us to accelerate the development of our new class of targeted cancer therapies."
Chief Medical Officer
Mid-size Biotech

Find out how our clinical trial and regulatory experts can help with your next study or program.


Learn More with These Resources

Fact Sheet

Medical Writing Fact Sheet


Accelerating positive outcomes in cancer trials: Veristat's ...

Case Study

Advancing to Your Next Milestone – Global Regulatory ...